Isabel Preeshagul, DO, MBS, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for newly diagnosed patients with metastatic non–small cell lung cancer (NSCLC) and no actionable mutations.
Osimertinib/Savolitinib Shows Meaningful Responses in EGFR+ NSCLC
Data from the phase 2 SAVANNAH trial may support savolitinib as a new treatment option following standard-of-care osimertinib in EGFR-mutated NSCLC.
Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology
Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.
Stereotactic Radiosurgery/TKIs Improves CNS Outcomes in EGFR/ALK+ NSCLC
Patients with non–small cell lung cancer and larger brain metastases may benefit most from the addition of up-front stereotactic radiosurgery to TKIs.
Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery
Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.
BLA Submitted for Teliso-V in Advanced EGFR Wild-type NSCLC
Data from the LUMINOSITY trial support the application for telisotuzumab vedotin in nonsquamous NSCLC harboring c-Met protein overexpression.
Neoadjuvant/Adjuvant Nivolumab/Chemo Approved by FDA in Resectable NSCLC
Findings from the phase 3 CheckMate 77T trial support the approval of nivolumab plus chemotherapy for resectable NSCLC.